ELI LILLY & COMPANYELI LILLY & COMPANYELI LILLY & COMPANY

ELI LILLY & COMPANY

No trades
See on Supercharts

Key facts today

Eli Lilly missed sales goals for Mounjaro and Zepbound, raising concerns in the obesity drug market. The company aims to boost Zepbound and will share late-stage results for orforglipron next year.
Eli Lilly's weight-loss drug Zepbound (Mounjaro) outperforms Novo Nordisk's Wegovy, highlighting competition in the GLP-1 market. The company is also working on oral versions of these treatments.
Redburn Atlantic raised its price target for Eli Lilly to $700 from $640, keeping a neutral rating. Analysts' targets for Eli Lilly range from $580 to $1,250, with an average rating of outperform.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪717.58 B‬EUR
‪4.75 B‬EUR
‪30.92 B‬EUR
‪850.72 M‬
Beta (1Y)
0.85
Employees (FY)
‪43 K‬
Change (1Y)
‪+4 K‬ +10.26%
Revenue / Employee (1Y)
‪793.58 K‬EUR
Net income / Employee (1Y)
‪121.87 K‬EUR

About Eli Lilly and Company


CEO
David A. Ricks
Headquarters
Indianapolis
Website
Founded
1876
FIGI
BBG00KG3YPD4
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US532457AM0
ELI LILLY 2025
Yield to maturity
6.07%
Maturity date
Jun 1, 2025
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.39%
Maturity date
Jun 15, 2044
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
5.32%
Maturity date
Aug 14, 2064
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
5.30%
Maturity date
Feb 9, 2064
US532457BS6
ELI LILLY 19/39
Yield to maturity
5.28%
Maturity date
Mar 15, 2039
LLY.GG
Eli Lilly and Company 6.77% 01-JAN-2036
Yield to maturity
5.24%
Maturity date
Jan 1, 2036
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053
Yield to maturity
5.23%
Maturity date
Feb 27, 2053
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.22%
Maturity date
Feb 27, 2063
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054
Yield to maturity
5.22%
Maturity date
Feb 9, 2054
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054
Yield to maturity
5.21%
Maturity date
Aug 14, 2054
US532457BT4
ELI LILLY 19/49
Yield to maturity
5.14%
Maturity date
Mar 15, 2049

Explore more bonds 

Frequently Asked Questions


The current price of 4LLY is 744.6 EUR — it has decreased by −1.95% in the past 24 hours. Watch ELI LILLY & COMPANY stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EUROTLX exchange ELI LILLY & COMPANY stocks are traded under the ticker 4LLY.
4LLY stock has fallen by −10.42% compared to the previous week, the month change is a −7.18% fall, over the last year ELI LILLY & COMPANY has showed a 38.92% increase.
We've gathered analysts' opinions on ELI LILLY & COMPANY future price: according to them, 4LLY price has a max estimate of 1,149.40 EUR and a min estimate of 643.67 EUR. Watch 4LLY chart and read a more detailed ELI LILLY & COMPANY stock forecast: see what analysts think of ELI LILLY & COMPANY and suggest that you do with its stocks.
4LLY reached its all-time high on Jul 15, 2024 with the price of 883.2 EUR, and its all-time low was 60.5 EUR and was reached on Mar 26, 2018. View more price dynamics on 4LLY chart.
See other stocks reaching their highest and lowest prices.
4LLY stock is 1.99% volatile and has beta coefficient of 0.85. Track ELI LILLY & COMPANY stock price on the chart and check out the list of the most volatile stocks — is ELI LILLY & COMPANY there?
Today ELI LILLY & COMPANY has the market capitalization of ‪714.86 B‬, it has decreased by −5.26% over the last week.
Yes, you can track ELI LILLY & COMPANY financials in yearly and quarterly reports right on TradingView.
ELI LILLY & COMPANY is going to release the next earnings report on Jan 30, 2025. Keep track of upcoming events with our Earnings Calendar.
4LLY earnings for the last quarter are 1.06 EUR per share, whereas the estimation was 1.28 EUR resulting in a −16.97% surprise. The estimated earnings for the next quarter are 5.02 EUR per share. See more details about ELI LILLY & COMPANY earnings.
ELI LILLY & COMPANY revenue for the last quarter amounts to ‪10.27 B‬ EUR, despite the estimated figure of ‪10.87 B‬ EUR. In the next quarter, revenue is expected to reach ‪12.89 B‬ EUR.
4LLY net income for the last quarter is ‪871.47 M‬ EUR, while the quarter before that showed ‪2.77 B‬ EUR of net income which accounts for −68.54% change. Track more ELI LILLY & COMPANY financial stats to get the full picture.
Yes, 4LLY dividends are paid quarterly. The last dividend per share was 1.18 EUR. As of today, Dividend Yield (TTM)% is 0.61%. Tracking ELI LILLY & COMPANY dividends might help you take more informed decisions.
ELI LILLY & COMPANY dividend yield was 0.78% in 2023, and payout ratio reached 77.91%. The year before the numbers were 1.07% and 56.79% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 5, 2024, the company has ‪43.00 K‬ employees. See our rating of the largest employees — is ELI LILLY & COMPANY on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ELI LILLY & COMPANY EBITDA is ‪14.47 B‬ EUR, and current EBITDA margin is 34.73%. See more stats in ELI LILLY & COMPANY financial statements.
Like other stocks, 4LLY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ELI LILLY & COMPANY stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ELI LILLY & COMPANY technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ELI LILLY & COMPANY stock shows the buy signal. See more of ELI LILLY & COMPANY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.